Targeted Therapy Options for EGFR Exon 20-Mutated mNSCLC

EP: 1.Biomarkers and Biomarker Testing in NSCLC

EP: 2.A Commentary on High PD-L1 Expression in NSCLC

EP: 3.Broad Molecular Testing Use in Adenocarcinoma versus Squamous Cell Carcinoma

EP: 4.Reflex Testing of Next Generation Sequencing (NGS)-Based Panels in NSCLC

EP: 5.Common Biomarker Testing Methodologies Utilized in NSCLC

EP: 6.Case 1: Metastatic NSCLC with an EGFR Exon 20 Insertion

EP: 7.A Pathologist Outlines Typical Tumor Tissue Processing Steps after Biopsy in NSCLC

EP: 8.First- and Second-Line Treatment Options for Patients with mNSCLC and an EGFR Exon 20 Mutation

EP: 9.Considerations for First-Line Treatment Selection for Patients with mNSCLC and Brain Metastases

EP: 10.Repeat Liquid and Tissue Biopsy Practices in mNSCLC

Now Viewing

EP: 11.Targeted Therapy Options for EGFR Exon 20-Mutated mNSCLC

EP: 12.Mobocertinib Safety and Efficacy Data in Patients with mNSCLC and an EGFR Exon 20 Mutation

EP: 13.CHRYSALIS Data on Amivantamab and a Comparative Efficacy Analysis of Mobocertinib vs Amivantamab

EP: 14.A Pathologist’s Commentary on The Heterogeneity of EGFR Exon 20 Insertions Found in NSCLC and Considerations for Results Reporting

EP: 15.Molecular Results Interpretation and Subsequent Treatment Selection for EGFR Exon 20 Mutation-Positive mNSCLC

EP: 16.Management of Adverse Events Following Mobocertinib and Strategies for Treatment Modification

EP: 17.Mobocertinib Treatment-Emergent EGFR Mutations and Subsequent Therapy Selection

EP: 18.RET Fusion-Positive mNSCLC: Case 2 Presentation and Molecular Testing Strategies

EP: 19.Selpercatinib and Pralsetinib for RET Fusion-Positive mNSCLC and Supporting Efficacy Data

EP: 20.Occurrence and Management of Selpercatinib- and Pralsetinib-Related AEs in Patients with RET Fusion-Positive mNSCLC

EP: 21.Potential Immunotherapy Use in Patients with mNSCLC and RET Alterations

EP: 22.Looking Towards the Future of Molecular Testing and Additional Treatment Options for Patients with mNSCLC

Joel Neal, MD, PhD: Zofia, we've spent a while talking about testing, but I think that's the point, it is what matters for non-small cell lung cancer, testing, testing, testing. If we don't find the targets, we can't give the targeted therapies. But you and I have spent a lot of time, and a lot of research interest in finding targeted therapies for EGFR Exon20 insertion, what are the therapies that you think about? And then we'll go through some of the data on each of these.

Zosia Piotrowska, MD: Yes. So, I think it's exciting to say in 2022 that we have two approved therapy options for this patient, and I think what else is also nice is that we have two drugs with different mechanisms of action. One is mobocertinib which is an oral EGFR tyrosine kinase inhibitor, and the second is amivantamab which is an intravenous antibody, which is a bispecific antibody targeting EGFR and MET. So, both of these are approved in the post-platinum chemotherapy setting for patients for EGFR Exon20 insertions, and we'll go through the data for both of these, but, for a patient like this who's young and healthy, I certainly hope that they would have access to both of these during their treatment course. And we may touch on as well on the fact that there's also a lot of ongoing clinical trials, and a lot of research going on in this area so, that in addition to these two drugs that have accelerated approval, we hope to have additional agents down the road, and certainly, this is a patient that I would also think about referring for clinical trials if there's an institution nearby if that's an option.

Joel Neal, MD, PhD: You also ran an ECOG-ACRIN clinical trial looking at the efficacy of third-generation EGFR TKI Osimertinib, what did you find from that? Before we had these FDA-approved options, I know many of us were talking about the role of osimertinib in high dose, specifically.

Zosia Piotrowska, MD: Exactly. So, the study that we ran was looking at osimertinib at a dose of 160 milligrams daily, so twice the approved dose for standard EGFR mutations, which was based on some pre-clinical data that suggested that the higher dose may be more active against the Exon20 insertions. So, a relatively small study, only about 20 patients enrolled, and we found that the activity of osimertinib 160 was modest. The response rate in our study was 24%, the median progression-free survival was about nine months. And interestingly, around the same time, there was a second study that was done in Europe called the POSITION20, same idea, the OC 160 for patients with Exon20 insertions, and very similar outcomes, so I think what that tells us is osimertinib can have some activity, although I would say that it's modest. You have to really be cautious with use of off-label osimertinib in these patients, and one word of caution is you can't assume that it will have the same CNS activity that it would for the common mutations. Again, I know we covered that earlier, but I think that is sometimes a reflex that people have to say, "Hey, we can try osimertinib, maybe it'll work in the brain," and you have to remember that across the board, it's less likely to work here. These are small studies, and we hope to generate more data, but so far, I would say that it does seem to have modest efficacy.